MedTrace Logo

Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas

NCT06863805 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-03-07

No results posted yet for this study

Summary

The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices

Conditions

  • Thyroid Carcinoma

Interventions

DIAGNOSTIC_TEST

4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA

For each patient enrolled in the present study, 4 EDTA tubes of peripheral blood will be collected to be used to obtain molecular profiling during scheduled laboratory controls as per normal clinical practice according to the following time schedule: * T0 = basal collection before initiation of systemic treatment; * T1 = sampling at 1 month after the start of systemic treatment; * T2 = sampling at 3 months (+/- 1 month) after the start of systemic treatment at the first instrumental re-evaluation of disease; * T3 = sampling at 6 months (+/- 1 month) from the start of systemic treatment at the time of instrumental disease reassessment; * T4 = sampling at the time of evidence of instrumental disease progression within 24 months of treatment initiation. The following analyses will be conducted on the samples thus collected: * multigenic analysis on ccf-DNA and ccf-RNA at baseline, i.e., before the initiation of systemic treatment; * isolation, counting and analysis of CTCs at baseline vi

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Manuela Ianni · Ospedale S. Orsola-Malpighi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06863805 on ClinicalTrials.gov